专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050054052A1 Modified interferon beta with reduced immunogenicity 有权
标题翻译：修饰的干扰素β具有降低的免疫原性
公开(公告)号：US20050054052A1
公开(公告)日：2005-03-10
申请号：US10471894
申请日：2002-03-15
申请人： Francis Carr , Graham Carter , Tim Jones , John Watkins
发明人： Francis Carr , Graham Carter , Tim Jones , John Watkins
IPC分类号： C12N15/09 , A61K38/21 , A61K39/00 , A61P31/12 , A61P37/02 , C07K7/08 , C07K14/565 , C12N15/22 , C12P21/02 , C07H21/04 , C07K14/765 , C12P21/04
CPC分类号： C07K14/565
摘要： The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human interferon beta to result in proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
摘要翻译：本发明涉及特别用于人，特别是用于治疗用途的多肽。所述多肽是修饰的多肽，其中所述修饰导致多肽在施用于人受试者时引起免疫应答的倾向降低。本发明特别涉及人类干扰素β的修饰，以产生当在体内使用时与任何未修饰的对应物基本上不具有免疫原性或较低免疫原性的蛋白质。

2. 发明授权

US5827694A DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides 失效
标题翻译：编码非人动物干扰素的DNA，载体和宿主，以及IFN多肽的重组产生
公开(公告)号：US5827694A
公开(公告)日：1998-10-27
申请号：US446171
申请日：1995-05-19
申请人： Daniel J. Capon , David V. Goeddel
发明人： Daniel J. Capon , David V. Goeddel
IPC分类号： A61K38/00 , C07K14/555 , C12N15/20 , C12N15/71 , C12N15/81 , C12N15/21 , C12N15/22 , C12N15/23
CPC分类号： C12N15/71 , C07K14/555 , C12N15/81 , A61K38/00
摘要： Distinct .alpha.-, .beta.- and .gamma.-interferon genes from various animal species have been identified, cloned and expressed to produce the corresponding non-human animal interferon proteins. Specifically disclosed are interferons of bovine, porcine, feline and rabbit origin.
摘要翻译：已经鉴定，克隆和表达来自各种动物物种的不同的α，β和γ-干扰素基因以产生相应的非人动物干扰素蛋白。具体公开的是牛，猪，猫和兔来源的干扰素。

3. 发明授权

US5468609A Production of interferon 失效
标题翻译：生产干扰素
公开(公告)号：US5468609A
公开(公告)日：1995-11-21
申请号：US425933
申请日：1982-09-28
申请人： Michel Revel , Pierre Tiollais
发明人： Michel Revel , Pierre Tiollais
IPC分类号： C12N15/09 , C07H21/02 , C07H21/04 , C07K14/54 , C07K14/565 , C12N15/00 , C12N15/22 , C12P19/34 , C12P21/00 , C12P21/02 , C12R1/19 , C12R1/91 , C07K14/52
CPC分类号： C07K14/5412 , C07K14/565
摘要： The present invention relates to a process to isolate genetic material (DNA) containing the nucleotide sequence coding for interferon in human fibroblastic cells which comprises cultivating cells producing interferon when exposed to an inducer of interferon, exposing same to such inducer, extracting messenger RNA from said induced cells, purifying the interferon messenger RNA, transcribing the messenger RNA into DNA and cloning the DNA in a suitable vector. Preferred cells are human diploid foreskin cells. The invention further relates to a process for engineering a bacterial strain to produce interferon polypeptide which comprises introducing a cloned interferon DNA into a suitable vector-carrier. A preferred vector-carrier is E. coli. The invention also relates to the mRNA of human interferon in highly purified form, to the mRNA of human interferon in .beta.1 highly purified form, to the mRNA of human interferon in .beta.2 highly purified form, to the DNA coding for a polypeptide having interferon activity, insertable in a vector, such as plasmid pBR322, and also to human interferon .beta.1 in highly purified form, and human interferon .beta.2 in highly purified form.
摘要翻译：本发明涉及一种分离含有人成纤维细胞中编码干扰素的核苷酸序列的遗传物质（DNA）的方法，其包括在暴露于干扰素诱导剂时培养产生干扰素的细胞，将其暴露于所述诱导物，从所述诱导物中提取信使RNA 诱导细胞，纯化干扰素信使RNA，将信使RNA转录成DNA，并将DNA克隆在合适的载体中。优选的细胞是人二倍体包皮细胞。本发明还涉及一种用于工程化细菌菌株以产生干扰素多肽的方法，其包括将克隆的干扰素DNA引入合适的载体载体中。优选的载体载体是大肠杆菌。本发明还涉及高度纯化形式的人干扰素的mRNA，β1高度纯化形式的人干扰素的mRNA与β2高度纯化形式的人干扰素的mRNA与编码具有干扰素的多肽的DNA 活性，可插入载体，如质粒pBR322，以及高度纯化形式的人干扰素β1和高度纯化形式的人干扰素β2。

4. 发明授权

US4966843A Expression of interferon genes in Chinese hamster ovary cells 失效
标题翻译：干扰素基因在中国仓鼠卵巢细胞中的表达
公开(公告)号：US4966843A
公开(公告)日：1990-10-30
申请号：US761180
申请日：1985-07-31
申请人： Francis P. McCormick , Michael A. Innis , Gordon M. Ringold
发明人： Francis P. McCormick , Michael A. Innis , Gordon M. Ringold
IPC分类号： A61K38/00 , C07K14/555 , C07K14/56 , C07K14/565 , C12N15/20 , C12N15/22
CPC分类号： C07K14/565 , C07K14/555 , C07K14/56 , A61K38/00 , Y10S435/811
摘要： DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The human recombinant interferon so produced contains glycans which are a subset of the population of glycans which are contained in the native counterpart, and may be used in therapeutic formulations. The CHO cells yield high levels of human interferon with no detectable amounts of host IFN, either constitutive or inductive.
摘要翻译：制备DNA构建体，其可操作地连接人干扰素基因，选择性真核标记基因，以及用于在中国仓鼠卵巢（CHO）细胞或其后代中表达人干扰素的启动子和表达控制序列。如此制备的人重组干扰素含有聚糖，其是包含在天然对应物中的聚糖群体的子集，并且可用于治疗制剂中。 CHO细胞产生高水平的人干扰素，没有可检测量的宿主IFN，组成型或归因的。

5. 发明授权

US10975392B2 Site-directed CRISPR/recombinase compositions and methods of integrating transgenes 有权
公开(公告)号：US10975392B2
公开(公告)日：2021-04-13
申请号：US15533164
申请日：2015-12-07
申请人： ABCAM PLC
发明人： Ruby Yanru Tsai
IPC分类号： C12N15/22 , C12N15/11 , C12N15/90 , C12N9/22 , C12N9/12
摘要： Disclosed herein are targeted chimeric polypeptides, compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy and cell therapy techniques. The chimeric polypeptide includes a CRISPR-Cas domain and a recombinase domain.

6. 发明授权

US10544420B2 Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids 有权
公开(公告)号：US10544420B2
公开(公告)日：2020-01-28
申请号：US16149025
申请日：2018-10-01
申请人： Antheia, Inc.
发明人： Christina D. Smolke , Derek H. Wells
IPC分类号： C12N15/22 , C12N9/06 , C12P17/18 , C12P17/12 , C12N15/62 , C12N9/02 , C12N9/90 , C12N15/52
摘要： The present disclosure provides systems and methods for increasing production of an alkaloid product through the epimerization of a (S)-1-benzylisoquinoline alkaloid to a (R)-1-benyzlisoquinoline alkaloid via an engineered epimerase in an engineered host cell. A (S)-1-benzylisoquinoline alkaloid is contacted with said engineered epimerase. Contacting said (S)-1-benzylisoquinoline alkaloid with said engineered epimerase converts said (S)-1-benzylisoquinoline alkaloid to said (R)-1-benzylisoquinoline alkaloid.

7. 发明授权

US08426166B2 Long-acting polypeptides and methods of producing same 有权
公开(公告)号：US08426166B2
公开(公告)日：2013-04-23
申请号：US13191478
申请日：2011-07-27
申请人： Fuad Fares , Udi Eyal Fima
发明人： Fuad Fares , Udi Eyal Fima
IPC分类号： C12N15/19 , C12N15/21 , C12N15/22 , C12N15/23 , C12N5/00 , A61K38/19 , A61K38/21 , C07K14/52 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/57
CPC分类号： C07K14/555 , A61K38/19 , A61K47/64 , C07K14/505 , C07K14/59 , C07K14/61 , C07K2319/00 , C07K2319/31 , C07K2319/35 , C07K2319/91
摘要： A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.

8. 发明授权

US5597711A Factor VIII binding domain of von Willebrand factor 失效
标题翻译：血管性血友病因子VIII因子结合域
公开(公告)号：US5597711A
公开(公告)日：1997-01-28
申请号：US410574
申请日：1995-03-24
申请人： Theodore S. Zimmerman , Paul A. Foster , Carol A. Fulcher
发明人： Theodore S. Zimmerman , Paul A. Foster , Carol A. Fulcher
IPC分类号： C12N15/09 , A61K38/00 , A61P7/02 , C07K1/22 , C07K14/00 , C07K14/745 , C07K14/755 , C07K16/00 , C07K16/36 , C12N5/10 , C12N15/02 , C12P21/00 , C12P21/02 , C12P21/08 , C12R1/91 , C07K1/14 , C12N15/22
CPC分类号： C07K16/36 , C07K14/755
摘要： Peptides which inhibit the binding of yon Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.
摘要翻译：抑制阴性血友病因子与因子VIII结合的肽。能够特异性结合含有因子VIII结合结构域的von Willebrand因子区域的单克隆抗体。改进制备因子VIII的方法。

9. 发明授权

US5510472A Production of recombinant human interferon-beta2 失效
标题翻译：重组人干扰素-β2的生产
公开(公告)号：US5510472A
公开(公告)日：1996-04-23
申请号：US883633
申请日：1992-05-15
申请人： Michel Revel , Pierre Tiollais
发明人： Michel Revel , Pierre Tiollais
IPC分类号： A61K38/00 , A61K38/21 , C07K14/54 , C07K14/565 , C12N15/22 , C12N15/24
CPC分类号： A61K38/215 , C07K14/5412 , C07K14/565
摘要： Human interferon-beta.sub.2.sbsb.A and interferon-beta.sub.2.sbsb.B are produced in purified form by recombinant DNA techniques. Two separate human genes have been identified which code for the production of IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B, respectively. The sequence of IFN-.beta..sub.2.sbsb.A cDNA is established. These genes and cDNA have been cloned into mammalian cells with an SV40 early promoter sequence and such genomic clones are capable of producing IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B. The antiviral activity of such recombinant IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B is demonstrated as well as other biological activity identifying them as human interferons.
摘要翻译：通过重组DNA技术以纯化形式产生人干扰素-β2A和干扰素-β2B。已经鉴定出分别编码IFN-β2A和IFN-β2B的两种分离的人类基因。建立了IFN-β2AcDNA序列。这些基因和cDNA已经用SV40早期启动子序列克隆到哺乳动物细胞中，并且这样的基因组克隆能够产生IFN-β2A和IFN-β2B。证明了这种重组IFN-β2A和IFN-β2B的抗病毒活性以及将其识别为人类干扰素的其他生物学活性。

10. 发明授权

US5468608A Production of interferon 失效
公开(公告)号：US5468608A
公开(公告)日：1995-11-21
申请号：US425935
申请日：1982-09-28
申请人： Michel Revel , Pierre Tiollais
发明人： Michel Revel , Pierre Tiollais
IPC分类号： C12N15/09 , C07H21/02 , C07H21/04 , C07K14/54 , C07K14/565 , C12N15/00 , C12N15/22 , C12P19/34 , C12P21/00 , C12P21/02 , C12R1/19 , C12R1/91
CPC分类号： C07K14/5412 , C07K14/565
摘要： The present invention relates to a process to isolate genetic material (DNA) containing the nucleotide sequence coding for interferon in human fibroblastic cells which comprises cultivating cells producing interferon when exposed to an inducer of interferon, exposing same to such inducer, extracting messenger RNA from said induced cells, purifying the interferon messenger RNA, transcribing the messenger RNA into DNA and cloning the DNA in a suitable vector. Preferred cells are human diploid foreskin cells. The invention further relates to a process for engineering a bacterial strain to produce interferon polypeptide which comprises introducing a cloned interferon DNA into a suitable vector-carrier. A preferred vector-carrier is E. coli. The invention also relates to the mRNA of human interferon in highly purified form, to the mRNA of human interferon in .beta.1 highly purified form, to the mRNA of human interferon in .beta.2 highly purified form, to the DNA coding for a polypeptide having interferon activity, insertable in a vector, such as plasmid pBR322, and also to human interferon .beta.1 in highly purified form, and human interferon .beta.2 in highly purified form.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式